Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MacroGenics closes $30.5mm Series B venture round

Executive Summary

MacroGenics (developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases) has completed its $30.5mm Series B venture round. Alta Partners and TPG Ventures led the round and were joined by new investors Mithra Group, Red Abbey Venture Partners, Emerging Technology Partners. Returning backers InterWest Partners, MPM Capital, OrbiMed, Cogene Biotech Ventures, Vivo Ventures, and Hunt Ventures also participated.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies